Full Service Biometric Solutions

Engaging a data-focused CRO is a better choice for risk mitigation in product development

A HUGE THANK YOU. Your commitment to the study’s success is immensely appreciated. Thank you for your exceptional dedication and support!
Clinical Data Management Leader
Leading Research Institute

Few CROs have an acute focus on data as you find with MMS. Here, our biometrics specialists manage all aspects of your program, from CRF design and build through final CSR. When you engage us to help manage data collection, analysis, and submission of your study data, the advantages are clear: better trial data execution, lower risk, stronger submissions, and accelerated outcomes.  
 
Our team of data managers, clinical programmers, biostatisticians, and data science experts take the stress out of your daily data-related responsibilities by integrating data operations directly into your global study team construct. This helps prevent extra work and added expense, while reducing risk to you – no matter if you are working with a full-service CRO or performing the clinical work yourself.
 
Whether you need to gain real time visibility to operational and clinical data, find insights via cross study comparison, or tackle Real-World Data (RWD) complexities, MMS is ready to use the right technologies and processes to do so competently and efficiently, having successfully supported regulatory submissions to health authorities throughout the world.
 
Through our proprietary Datacise® platform, Sponsors like you see near real-time data status and emerging trends to accelerate and de-risk your trials. This is often used to identify and strategize on emergent risks quickly, whether it be in trial data flow, adverse events of interest, safety signals, and the like.

We love working with Sponsors to ensure that all studies start and conclude successfully, addressing important needs that include:

  • Providing real-time visibility into operational and clinical data
  • Incorporating multiple data vendors into a study
  • Automating data quality checks
  • Pooling multiple studies into analyses
  • Comparing results across studies
  • Ensuring deliverables adhere to industry standards
  • Providing support/consultation as an extension of your own study team

To help meet these needs we use several standard and proprietary tools, including Zelta, SAS, R, and NQuery. Additionally, MMS proprietary tools such as Datacise® with AI/ML (Machine Learning) raise efficiencies and add further value to your projects.

MMS Can Manage Vendors For You

Given our data-focused expertise, MMS removes the frustration that can arise from managing multiple vendors. By handling this process for you, MMS will receive the data from multiple sources and ensure it is quality checked and consolidated into industry standard formats such as STDM and ADAM for analysis and submission requirements.

Gain Insights Quicker

MMS can provide you with earlier insights into your data. Since we are intimately familiar with all major EDC systems, including Zelta and Rave, MMS data scientists can capture study information as soon as it is collected to present your data management queries and clinical data sooner.

Greater Consistency and Accuracy

MMS works as a team to ensure that your data receives consistent treatment throughout the drug development process. Data Science works closely with Biostatistics and Programming to ensure that our statistics presented are consistent and honor the statistical analysis plan (SAP).

Managed Studies

The “One MMS” motto comes into full effect as we manage all the data hand-off from one specialty area to another. In fact, we put in place some of our own tools, such as Datacise® Workbench and Explore, as well as an automated process for creating immutable tables (in-text tables) for direct importing into your CSR to expedite this process.

At MMS, you can expect world-class tools and technologies to ensure your project’s success, including:

  • Electronic Data Capture using Zelta, Rave, and others
  • Datacise® Workbench to automate SDTM (Study Data Tabulation Model) creation
  • PVantage™ to assist with medical review
  • SAS and R to create consistent and accurate statistics
  • Datacise® to help you quickly gain insights into your study’s data
  • Statsols Nquery for sample size estimations and power calculations

Given the experience and familiarity with these tools, MMS delvers results to you in a more efficient and timely manner. Automation is integrated into MMS processes where it makes sense, and we incorporate data checks at key points in the data chain to ensure the utmost quality.

Specifically, MMS does this by:

  • Accelerating your study’s implementation by leveraging pre-built macros and forms to accelerate SAS programming and EDC builds
  • Quickly revealing data quality issues by incorporating real-time edit checks
  • Implementing holistic data checks to identify potential issues across the study data, such as missed visits
  • Focused reviews of data anomalies impacting the estimands of your study
  • Delivering validated dashboards using automated rival programming techniques
Taking it to the Program Level

As one study follows another, MMS can help you answer some big questions: Is this study comparable to previous studies? Do the trial assumptions hold, based on the data (e.g., comparing event frequency)?

MMS is different than other biometrics CRO vendors, as we bring a long-term vision and work together with you from the start to get your data organized and ensure that these types of questions are easily answered as they arise.

Whether MMS starts with you from the first study or we join later in the product development journey, you do not have to worry about gathering and reporting across studies. MMS routinely incorporates historical data from multiple sources and formats to deliver a common set of cross-study data to analyze via Datacise® Explore. Similarly, for NDA submissions, we can handle your Integrated Submission for Safety (ISS) and/or Integrated submission for Efficacy (ISE) pooling, analyses, and packaging towards that goal.

Tackle Big Data

One challenge that small to mid-sized companies quickly face is how to scale up. In the beginning, it is easy to manage data with Excel, but as studies grow or the need to incorporate RWD into a project arises, it’s easy for many to outgrow their own capacity.
At MMS, advanced data engineering tools and processes ensure that data can be properly ingested from multiple providers and be combined to provide meaningful information.

We are just as comfortable handling complex data requirements for a rare disease study as we are handling data requirements for a small, simpler study. Given our experience with working with Environmental, Health, and Safety (EHS) and insurance claims data, MMS will evolve your RWD into the RWE (Real World Evidence) that can be used in submissions to to global regulatory bodies.

Additionally, for any type of study or program of studies, MMS can:

  • Augmenting your program with real world and safety data
  • Providing historical control data for your study
  • Assisting in planning your studies based on RWD and simulations
Biometrics Service Areas

Driven by quality, our global experts at MMS approach every Biometrics and Data Science deliverable as a top priority, no matter how big or small the project may be. You can expect in-depth, thoughtful conversations with team members, knowing that they are thought leaders, invited speakers, and change makers in industry groups across the globe.

Suggested For You

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

perspectives

August 20th, 2024

Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer